Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
Systemic lupus erythematosus
•
Benign Hematology
•
Anticoagulation
•
Hospital Medicine
How would you approach a patient with SLE and catastrophic antiphospholipid antibody system that has not responded to heparin, steroids, and PLEX?
How do you decide amongst other therapies such as eculizumab, rituximab, cyclophosphamide, IVIg?
Related Questions
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Would you be comfortable combining rituximab with voclosporin in patients with lupus nephritis not responding to standard therapy?
What factors do you weigh most heavily when choosing between belimumab and voclosporin as part of a triple therapy regimen for newly diagnosed class IV LN?
Would you accept the diagnosis of SLE on the basis of an AVISE CTD panel where the results just showed a positive EC4d or BC4d, positive ANA>1/80 + one clinical criteria such as multiple tender joints but did otherwise not fulfill criteria for SLE?
Would you start hydroxychloroquine (or another DMARD) in a mid-20s female patient with positive ANA, SSA, SSB, and dsDNA, whose only clinical manifestation is intermittent parotid gland swelling?
Would you pursue immunosuppression in a patient with mixed connective tissue disease presenting primarily as dysautonomia assuming other causes have been ruled out?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
What is the appropriate interval to obtain a hydroxychloroquine level after making a dosage adjustment?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?